Wong W T, Chan M K, Li M K, Wong W S, Yin P D, Cheng I K
Department of Microbiology, University of Hong Kong.
Scand J Infect Dis Suppl. 1988;56:22-7.
The study compared the efficacy and safety of norfloxacin to those of co-trimoxazole in the treatment of urinary tract infections (UTI). A total of 172 adults, 42 men and 130 women were recruited and randomly allocated to norfloxacin or co-trimoxazole using a double-blind study design. Patients with lower UTI received norfloxacin 200 mg or co-trimoxazole (160 mg of trimethoprim plus 800 mg of sulphamethoxazole) b.i.d. for seven days. In patients with upper UTI, the norfloxacin dose was 400 mg b.i.d. for seven days. Eleven to 14 days after treatment, the bacteriological cure rates were 96.8% and 83.3% and the clinical cure rates were 96.9% and 89.9% for norfloxacin and co-trimoxazole, respectively. A few patients complained of gastrointestinal symptoms but there were few other side-effects and the treatments were well tolerated. In conclusion, both norfloxacin and co-trimoxazole were well tolerated but norfloxacin gave higher cure rates.
该研究比较了诺氟沙星与复方新诺明治疗尿路感染(UTI)的疗效和安全性。总共招募了172名成年人,其中42名男性和130名女性,并采用双盲研究设计将他们随机分配至诺氟沙星组或复方新诺明组。下尿路感染患者接受诺氟沙星200毫克或复方新诺明(160毫克甲氧苄啶加800毫克磺胺甲恶唑),每日两次,共七天。上尿路感染患者的诺氟沙星剂量为每日两次,每次400毫克,共七天。治疗后11至14天,诺氟沙星和复方新诺明的细菌学治愈率分别为96.8%和83.3%,临床治愈率分别为96.9%和89.9%。少数患者抱怨有胃肠道症状,但其他副作用很少,且治疗耐受性良好。总之,诺氟沙星和复方新诺明的耐受性都很好,但诺氟沙星的治愈率更高。